A carregar...
Initial Experience With CMC-544 (Inotuzumab Ozogamicin) in Pediatric Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Survival is poor in pediatric patients with relapsed or refractory acute B-cell lymphoblastic leukemia (ALL) and therapeutic options are limited. CMC-544 (inotuzumab ozogamicin) has shown significant activity in adult patients with relapsed and refractory ALL. We evaluated CMC-544 in pediatric patie...
Na minha lista:
| Publicado no: | Pediatr Blood Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5042143/ https://ncbi.nlm.nih.gov/pubmed/24000241 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24721 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|